9.2 Biology and pharmacology of anti-VEGF therapies
Summary
VEGF is known to play a key role in the development of DME. This growth factor acts on proteins in tight junctions, thus causing the breakdown of the blood-retinal barrier. The mechanisms by which VEGF induces neovascularization in PDR are multifactorial; however, several critical factors have been identified.
Quiz Module 9.2
Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account
To validate your answers and keep track of your progress please sign in or register a new account
1. True or False: Vascular endothelial growth factor concentrations are elevated in patients with DME. The compound acts to disrupt tight junctions resulting in a breakdown of the blood-retinal barrier.
2. Which of the following does not appear to be a predictor of BCVA gains of ≥15 letters with anti-VEGF therapy?